These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 39094579)

  • 21. Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain.
    Guerra D; Radić L; Brinkkemper M; Poniman M; van der Maas L; Torres JL; Ward AB; Sliepen K; Schinkel J; Sanders RW; van Gils MJ; Beaumont T
    Hum Vaccin Immunother; 2024 Dec; 20(1):2388344. PubMed ID: 39165108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant.
    Laghlali G; Wiest MJ; Karadag D; Warang P; O'Konek JJ; Chang LA; Park SC; Yan V; Farazuddin M; Janczak KW; García-Sastre A; Baker JR; Wong PT; Schotsaert M
    Mol Ther; 2024 Dec; 32(12):4448-4466. PubMed ID: 39489918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies.
    Greaney AJ; Starr TN; Barnes CO; Weisblum Y; Schmidt F; Caskey M; Gaebler C; Cho A; Agudelo M; Finkin S; Wang Z; Poston D; Muecksch F; Hatziioannou T; Bieniasz PD; Robbiani DF; Nussenzweig MC; Bjorkman PJ; Bloom JD
    Nat Commun; 2021 Jul; 12(1):4196. PubMed ID: 34234131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ancestral SARS-CoV-2-Driven Antibody Repertoire Diversity in an Unvaccinated Individual Correlates with Expanded Neutralization Breadth.
    Deshpande S; Ansari MY; Sutar J; Das P; Hingankar N; Mukherjee S; Jayal P; Singh S; Anantharaj A; Singh J; Chattopadhyay S; Raghavan S; Gosain M; Chauhan S; Shrivas S; Prasad C; Chauhan S; Sharma N; Jana P; Thiruvengadam R; Kshetrapal P; Wadhwa N; Das B; Batra G; Medigeshi G; Sok D; Bhatnagar S; Garg PK; Bhattacharya J
    Microbiol Spectr; 2023 Mar; 11(2):e0433222. PubMed ID: 36946746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees.
    Geers D; Shamier MC; Bogers S; den Hartog G; Gommers L; Nieuwkoop NN; Schmitz KS; Rijsbergen LC; van Osch JAT; Dijkhuizen E; Smits G; Comvalius A; van Mourik D; Caniels TG; van Gils MJ; Sanders RW; Oude Munnink BB; Molenkamp R; de Jager HJ; Haagmans BL; de Swart RL; Koopmans MPG; van Binnendijk RS; de Vries RD; GeurtsvanKessel CH
    Sci Immunol; 2021 May; 6(59):. PubMed ID: 34035118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring distinct modes of inter-spike cross-linking for enhanced neutralization by SARS-CoV-2 antibodies.
    Nan X; Li Y; Zhang R; Wang R; Lv N; Li J; Chen Y; Zhou B; Wang Y; Wang Z; Zhu J; Chen J; Li J; Chen W; Zhang Q; Shi X; Zhao C; Chen C; Liu Z; Zhao Y; Liu D; Wang X; Yan LT; Li T; Zhang L; Yang YR
    Nat Commun; 2024 Dec; 15(1):10578. PubMed ID: 39632831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R
    Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population Immunity and Covid-19 Severity with Omicron Variant in South Africa.
    Madhi SA; Kwatra G; Myers JE; Jassat W; Dhar N; Mukendi CK; Nana AJ; Blumberg L; Welch R; Ngorima-Mabhena N; Mutevedzi PC
    N Engl J Med; 2022 Apr; 386(14):1314-1326. PubMed ID: 35196424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies.
    Greaney AJ; Loes AN; Crawford KHD; Starr TN; Malone KD; Chu HY; Bloom JD
    Cell Host Microbe; 2021 Mar; 29(3):463-476.e6. PubMed ID: 33592168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection.
    Greaney AJ; Loes AN; Gentles LE; Crawford KHD; Starr TN; Malone KD; Chu HY; Bloom JD
    Sci Transl Med; 2021 Jun; 13(600):. PubMed ID: 34103407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.
    Huang KA; Chen X; Mohapatra A; Nguyen HTV; Schimanski L; Tan TK; Rijal P; Vester SK; Hills RA; Howarth M; Keeffe JR; Cohen AA; Kakutani LM; Wu YM; Shahed-Al-Mahmud M; Chou YC; Bjorkman PJ; Townsend AR; Ma C
    Nat Commun; 2023 Jan; 14(1):311. PubMed ID: 36658148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term COVID-19 vaccine- and Omicron infection-induced humoral and cell-mediated immunity.
    Belik M; Reinholm A; Kolehmainen P; Heroum J; Maljanen S; Altan E; Österlund P; Laine L; Ritvos O; Pasternack A; Naves RA; Iakubovskaia A; Barkoff AM; He Q; Lempainen J; Tähtinen PA; Ivaska L; Jalkanen P; Julkunen I; Kakkola L
    Front Immunol; 2024; 15():1494432. PubMed ID: 39640263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein.
    Mendoza-Ramírez NJ; García-Cordero J; Shrivastava G; Cedillo-Barrón L
    J Immunol Res; 2024; 2024():9313267. PubMed ID: 38939745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study.
    Rizvi NB; Bibi M; Rana MZ; Zaffar S; Farooq H
    Front Immunol; 2024; 15():1448408. PubMed ID: 39606247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines.
    Bartsch YC; Tong X; Kang J; Avendaño MJ; Serrano EF; García-Salum T; Pardo-Roa C; Riquelme A; Cai Y; Renzi I; Stewart-Jones G; Chen B; Medina RA; Alter G
    Sci Transl Med; 2022 Apr; 14(642):eabn9243. PubMed ID: 35289637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.
    Klinkardt U; Schunk M; Ervin J; Schindler C; Sugimoto D; Rankin B; Amann R; Monti M; Kutschenko A; Schumacher C; Huber K; Zeder A; Heikkila N; Didierlaurent AM; Schwarz SE; Derouazi M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2410574. PubMed ID: 39397784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines.
    Liang CY; Raju S; Liu Z; Li Y; Asthagiri Arunkumar G; Case JB; Scheaffer SM; Zost SJ; Acreman CM; Gagne M; Andrew SF; Carvalho Dos Anjos DC; Foulds KE; McLellan JS; Crowe JE; Douek DC; Whelan SPJ; Elbashir SM; Edwards DK; Diamond MS
    Nature; 2024 Jun; 630(8018):950-960. PubMed ID: 38749479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural insight into broadening SARS-CoV-2 neutralization by an antibody cocktail harbouring both NTD and RBD potent antibodies.
    Jiang W; Jiang Y; Sun H; Deng T; Yu K; Fang Q; Ge H; Lan M; Lin Y; Fang Z; Zhang Y; Zhou L; Li T; Yu H; Zheng Q; Li S; Xia N; Gu Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2406300. PubMed ID: 39470577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological insights into COVID-19 in Southern Nigeria.
    Ugwu CA; Alao O; John OG; Akinnawo B; Ajayi I; Odebode O; Bejide I; Campbell A; Campbell J; Adole JA; B Olawoye I; Akano K; Okolie J; Eromon P; Olaitan P; Olagunoye A; Adebayo I; Adebayo V; Babalola E; Abioye O; Ajayi N; Ogah E; Ukwaja K; Okoro S; Oje O; Kingsley OC; Eke M; Onyia V; Achonduh-Atijegbe O; Ewah FE; Obasi M; Igwe V; Ayodeji O; Chukwuyem A; Owhin S; Oyejide N; Abah S; Ingbian W; Osoba M; Alebiosu A; Nadesalingam A; Aguinam ET; Carnell G; Krause N; Chan A; George C; Kinsley R; Tonks P; Temperton N; Heeney J; Happi C
    Front Immunol; 2024; 15():1305586. PubMed ID: 38322252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants.
    Rodriguez-Aponte SA; Dalvie NC; Wong TY; Johnston RS; Naranjo CA; Bajoria S; Kumru OS; Kaur K; Russ BP; Lee KS; Cyphert HA; Barbier M; Rao HD; Rajurkar MP; Lothe RR; Shaligram US; Batwal S; Chandrasekaran R; Nagar G; Kleanthous H; Biswas S; Bevere JR; Joshi SB; Volkin DB; Damron FH; Love JC
    Vaccine; 2023 Jan; 41(5):1108-1118. PubMed ID: 36610932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.